Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 61, Issue 1 , Pages 94-98 , January 2008

Bisphosphonates and avascular necrosis of the mandible: Case report and review of the literature

  • Dylan J. Murray

      Affiliations

    • Division of Plastic Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • Wharton Head & Neck Centre, University Health Network, Toronto, Ontario, Canada
    • ,
  • Martin J.J. Vesely

      Affiliations

    • Division of Plastic Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • Wharton Head & Neck Centre, University Health Network, Toronto, Ontario, Canada
    • ,
  • Christine B. Novak

      Affiliations

    • Wharton Head & Neck Centre, University Health Network, Toronto, Ontario, Canada
    • ,
  • Jonathan Irish

      Affiliations

    • Wharton Head & Neck Centre, University Health Network, Toronto, Ontario, Canada
    • Department of Otolaryngology – Head & Neck Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Michael Crump

      Affiliations

    • Department of Medical Oncology & Hematology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Peter C. Neligan

      Affiliations

    • Division of Plastic Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • Wharton Head & Neck Centre, University Health Network, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Division of Plastic Surgery, Toronto General Hospital, 8N-865 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada. Tel.: +1 416 340 3449; fax: +1 416 340 4403.

Received 8 May 2006 ,Accepted 6 June 2006.

References 

  1. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–534
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117
  3. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61(9):1104–1107
  4. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99–102[discussion 99–102]
  5. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99–102[discussion 99–102]
  6. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99–102[discussion 99–102]
  7. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104(1):83–93
  8. Zarychanski R, Elphee E, Walton P, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006;81(1):73–75
  9. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996;137(6):2324–2333
  10. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34(2):120–123
  11. Hughes DE, MacDonald BR, Russell RG, et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83(6):1930–1935
  12. Sahni M, Collin P, Felix R, et al. Direct effect of bisphosphonates on isolated rat osteoclasts. J Bone Miner Res. 1992;17(Suppl. 1):189
  13. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055–1061
  14. Teronen O, Laitinen M, Salo T, et al. Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma. Blood. 2000;96(12):4006–4007
  15. Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist. 2004;9(Suppl. 4):38–47
  16. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;8(5):1080–1084
  17. Timothy AR, Tucker AK, Malpas JS, et al. Osteonecrosis after intensive chemotherapy for Hodgkin's disease. Lancet. 1978;1(8056):154
  18. Winquist EW, Bauman GS, Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol. 2001;24(6):603–606
  19. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003;61(10):1238–1239
  20. Agarwala S, Sule A, Pai BU, et al. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford). 2002;41(3):346–347
  21. Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine. 2006;73(1):7–9
  22. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5):283–288
  23. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005;63(5):682–689
  24. Hellstein JW, Marek CL. Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg. 2004;62(12):1563–1565
  25. Herrera D, Roldan S, Santacruz I, et al. Differences in antimicrobial activity of four commercial 0.12% chlorhexidine mouthrinse formulations: an in vitro contact test and salivary bacterial counts study. J Clin Periodontol. 2003;30(4):307–314

PII: S1748-6815(06)00481-5

doi: 10.1016/j.bjps.2006.06.017

Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 61, Issue 1 , Pages 94-98 , January 2008

Article Tools

* Image Usage & Resolution